Kenan SAĞLAM, Ümit AYDOĞAN, Oktay SARI, İsmail ATACAN, Tuncer ÇAYCI, Adem PARLAK, Deniz Engin GÖK

The effects of valsartan treatment on visfatin levels and lipid profiles in newly diagnosed hypertensives

In this study, the curative effect of valsartan on hypertension based on its effect on visfatin levels and lipid profiles was investigated. Materials and methods: Forty patients aged 38-60 with hypertension were included in the study. In order to determine initial visfatin levels and lipid profiles, blood samples were taken from the patients and all were started on 80-mg valsartan tablets. All patients were monitored for 12 weeks. Results: By using multivariate regression analysis, it was determined that visfatin levels affected systolic blood pressure (SBP) (P = 0.012, beta; -0.43, 95% CI: -0.092 to -0.012). After the patients received the valsartan treatment for 12 weeks, a significant increase in visfatin levels was observed (pre- and posttreatment, respectively: 0.42 ± 0.22 ng/mL and 0.71 ± 0.36 ng/mL, P < 0.001). When the lipid profile changes of patients were examined, only low-density lipoprotein (LDL) levels showed a statistically significant change (pre- and posttreatment, respectively: 150.32 ± 13.22 mg/dL and 143.82 ± 7.53 mg/dL, P = 0.008). Conclusion: In this study, it was found that visfatin levels affected SBP in newly diagnosed hypertensive patients and valsartan treatment increased visfatin levels. In addition, the use of valsartan reduced LDL levels.

Anahtar Kelimeler:

Key words: Hypertension, valsartan, visfatin, lipid, multivariate regression analysis

The effects of valsartan treatment on visfatin levels and lipid profiles in newly diagnosed hypertensives

Keywords:

Key words: Hypertension, valsartan, visfatin, lipid, multivariate regression analysis,

PDF

___

Karamahmutoğlu F. Dirençli Hipertansiyonun Vücut Kitle İndeksi ile İlişkisi. Uzmanlık Tezi. Okmeydani Eğitim ve Araştırma Hastanesi, 1. Dahiliye Kliniği; 2007.
Bostan M, Şatıroğlu Ö, Uydu HA, Çicek Y, Çanga A, Karadağ Z et al. Distribution of coronary artery risk factors: a regional analysis. Turk J Med Sci 2011; 41: 317–24.
Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases. Circ Res 2000; 87: 840–4.
Kırkpantur A, Altun B. Endotel disfonksiyonu ve hipertansiyon. Türk J Cardiol 2006; 9: 55–61.
Romacho T, Azcutia V, Vazquez-Bella M, Matesanz N, Cercas E, Nevado J et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009; 52: 2455–63.
Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009; 71: 202–7.
Wozniak SE, Gee LL, Watchel MS, Frezza EE. Adipose tissue: the new endocrine organ? Dig Dis Sci 2009; 54: 1847–56.
Yilmaz MI, Saglam M, Carrero JJ, Quereshi AR, Caglar K, Eyileten T et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959–65.
Dogru T, Sonmez A, Tasci I, Yilmaz MI, Erdem G, Erturk H et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertens 2007; 21: 173–5.
Grill S, Rusterholz C, Zanetti-Dallenbach R, Tercanli S, Holzgreve W, Hahn S et al. Potential markers of preeclampsia – a review. Reprod Biol Endocrinol 2009; 7: 70–84.
Arner P. Editorial: Visfatin – a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 28–30.
Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ et al. Elevated plasma level of visfatin/pre-B cell colony- enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295–9.
Hammerstedt A, Pihlajamaki J, Rotter Sopasakis V, Gogg S, Jansson PA, Laakso M et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 2006; 91: 1181–4.
Haider DG, Schindler K, Schaller G, Prager G, Woltz M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578–81.
Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911–6.
Taskesen D, Kirel B, Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 2012; 4: 75–9.
Saddi-Rosa P, Oliveira CSV, Giuffrida FM, Reis AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010; 2: 21.
Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G et al. Serum levels of vaspin and visfatin in patients with coronary artery disease – Kozani study. Clinica Chimica Acta 2011; 412: 48–52.
Gunes F, Akbal E, Cakir E, Akyurek O, Altinbas M, Ozbek M. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients. Intern Med 2012; 51: 553–7.
Wang P, Bai C, Xu QY, Xu TY, Su DF, Sassard J et al. Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats. Clin Exp Pharmacol Physiol 2010; 37: 894–9.
Olszanecka-Glinianowicz M, Kocełak P, Nylec M, Chudek J, Zahorska-Markiewicz B. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Arch Med Sci 2012; 8: 214–8.
Storka A, Vojtassako E, Mueller M, Kapiotas S, Haider DG, Jungbauer A et al. Angiotensin inhibition stimulates PPARY and the release of visfatin. Eur J Clin Invest 2008; 38: 820–6.
Saraç S, Saraç F, Tütüncüoglu P. Effects of telmisartan and valsartan on insulin resistance, visfatin and adiponectin levels in hypertensive patients with metabolic syndrome. Acta Endocrinologica (Buc) 2008; 4: 23–32.
Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med 1988; 148: 1280–8.
Grimm RG, Leon AS, Hunning DB, Lenz K, Hannan P, Blackburn H. Effects of thiazide diuretics on blood lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med 1981; 94: 7–11.
Moan A, Hoieggen A, Seljeflot I, Risanger T, Arnesen H, Kjeldsen SE. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14: 1093–7.
Ogihara T, Yoshinaga K. The clinical efficacy and tolerability of the angiotensin II receptor antogonist losartan in Japanese patients with hypertension. Blood Press 1996; 5: 78–81.
Trenkwalder P, Mehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose hemostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 1997; 11: 81–3.
de Zeeuw D, Gansevoort RT, Dullaart RPF, Jong PE. Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. J Hypertens 1995; 13: S53– 8.
Lerch M, Teuscher U, Beissner P, Schneider M, Shaw SG, Weidmann P. Effects of angiotensin II receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J Cardiovasc Pharmacol 1998; 31: 576–80.
Kyvelou SMG, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Zervoudaki AI, Pietri PG et al. Effects of angiotensin II receptor blockers on lipid profile: an open multidrug comparison trial. Hellenic J Cardiol 2006; 47: 21–8.
Hanefeld M, Abletshauer C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 2001; 29: 270–9.
Barutçuoğlu B, Parıldar Z, Mutaf MI, Özmen D, Alioğlu E, Habif S et al. Effect of telmisartan on vascular endothelium in hypertensive and type 2 diabetic hypertensive patients. Turk J Med Sci 2010; 40: 239–48.
Kirk JK. Angiotensin II receptor antagonists: their place in therapy. Am Fam Phys 1999; 59: 3140–8.